Prostate Cell News Volume 11.14 | Apr 24 2020

TOP STORY

IKBKE Activity Enhances AR Levels in Advanced Prostate Cancer via Modulation of the Hippo Pathway

Significant inhibition of androgen receptor (AR) regulated gene expression was observed upon siRNA-mediated IKBKE depletion or pharmacological inhibition due to inhibited AR gene expression in multiple cell line models. [Nucleic Acids Res] Full Article

(Ranked by impact factor of the journal)

Prostate Cancer Cell-Intrinsic Interferon Signaling Regulates Dormancy and Metastatic Outgrowth in Bone

Scientists demonstrated that loss of tumor-intrinsic type I IFN occurred in proliferating prostate cancer cells in bone. This loss suppresses tumor immunogenicity and therapeutic response and promotes bone cell activation to drive cancer progression. [EMBO Rep] Abstract | Graphical Abstract

Replication Study: A Coding-Independent Function of Gene and Pseudogene mRNAs Regulates Tumor Biology

PTEN and/or PTENP1 depletion in DU145 cells decreased PTEN protein expression, and depletion of PTEN and/or PTENP1 increased DU145 proliferation compared to non-targeting siRNA. [eLife] Full Article

Role of CYP3A5 in Modulating Androgen Receptor Signaling and Its Relevance to African American Men with Prostate Cancer

Researchers showed that the CYP3A5 inducers promoted androgen receptor (AR) nuclear translocation, downstream signaling, and cell growth, whereas CYP3A5 inhibitors abrogated them. [Cancers] Full Article

ARNT-Dependent CCR8 Reprogrammed LDH Isoform Expression Correlates with Poor Clinical Outcomes of Prostate Cancer

The depletion of CC-chemokine ligand-18 (CCR8) reduced the ability of CCL18 to promote the proliferation, migration, and lactate production of prostate cancer cells. [Mol Carcinog] Abstract

Pharmacological and Genetic Targeting of 5-Lipoxygenase Interrupts C-Myc Oncogenic Signaling and Kills Enzalutamide-Resistant Prostate Cancer Cells via Apoptosis

Researchers investigated the effects of pharmacological and genetic inhibition of 5-lipoxygenase on cell proliferation, apoptosis and invasive potential of enzalutamide-resistant prostate cancer cells. [Sci Rep] Full Article

The Expression of YAP1 Is Increased in High-Grade Prostatic Adenocarcinoma but Is Reduced in Neuroendocrine Prostate Cancer

YAP1 expression was present in the basal epithelial cells in benign prostatic tissues, lost in low-grade prostate cancer, but elevated in high-grade prostate adenocarcinomas. [Prostate Cancer Prostatic Dis] Abstract

Knockdown of GSG2 Inhibits Prostate Cancer Progression In Vitro and In Vivo

Germ cell-specific gene 2 protein (GSG2) expression was upregulated in prostate cancer tissues and human prostate cancer cell lines PC-3 and DU 145. High expression of GSG2 in tumor samples was associated with progressed tumors. [Int J Oncol] Full Article

Gli2 Mediates the Development of Castration-Resistant Prostate Cancer

Gli2 knockdown sensitized both androgen-dependent and -independent prostate cancer cells to the antiandrogen drug Casodex and prevented the outgrowth of LNCaP prostate cancer cells. [Int J Oncol] Full Article

Identification of Cofilin-1 as a Novel Mediator for the Metastatic Potentials and Chemoresistance of the Prostate Cancer Cells

The authors compared the protein profiles of two prostate cancer cell lines with different metastatic potentials, and identified cofilin-1 was one of the most differentially expressed proteins between two cell lines. [Eur J Pharmacol] Abstract

Subscribe to one of our other 19 science newsletters such as Mammary Cell News & ESC & iPSC News.

The Genetic Landscapes of Urological Cancers and Their Clinical Implications in the Era of High-Throughput Genome Analysis

The authors summarize data available from The Cancer Genome Atlas and other major studies, and explore the clinical implications of specific genetic alterations, both prognostically and therapeutically, in four major urological cancers. [BJU Int] Abstract

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Myovant Sciences Submits New Drug Application (NDA) to the FDA for Once-Daily, Oral Relugolix for the Treatment of Men with Advanced Prostate Cancer

Myovant Sciences announced that it has submitted a New Drug Application to the FDA for once-daily, oral relugolix for the treatment of men with advanced prostate cancer. [Myovant Sciences] Press Release

LYNPARZA^® (Olaparib) Demonstrated Overall Survival Benefit in Phase III PROfound Trial for BRCA1/2 or ATM-Mutated Metastatic Castration-Resistant Prostate Cancer

AstraZeneca and Merck announced further positive results from the Phase III PROfound trial evaluating LYNPARZA in men with metastatic castration-resistant prostate cancer who have a homologous recombination repair gene mutation. [AstraZeneca plc] Press Release

Open Science Takes On the Coronavirus Pandemic

When reports emerged in late 2019 of an outbreak of a new coronavirus centred in Wuhan, China, researchers at the virological-analysis website Nextstrain were ready. The open-source project tracks the spread of viruses through genetic variations in the sequences that scientists find. [Nature News] Editorial

Untapped Potential: More US Labs Could Be Providing Tests for Coronavirus

A survey of more than 4,000 researchers in the United States suggests that better coordination at an institutional and national level could make hundreds of thousands more tests for coronavirus available. [Nature News] Editorial

In light of COVID-19, many conferences are being cancelled or postponed. As such:

We are suspending new event postings in our newsletters and on Twitter.
We will strive to keep our current event listings updated with event status.
We encourage you to visit event sites directly for updates.

Visit our events page to see a complete list of events in the community.

NEW Assistant Professor – Cell Cycle and Cancer Biology (Oklahoma Medical Research Foundation)

Postdoctoral Researcher – Translational Cancer Research (Johannes Kepler University of Linz)

Associate Professor – Cancer Biology (University of Cincinnati)

Postdoctoral Scholar – Tumor Metabolism and DNA Repair (The Ohio State University)

Postdoctoral Position – Cancer Cell Biology and Drug Discovery (University of Luxembourg)

Postdoctoral Research Fellow – Molecular Oncology (Genentech)

Postdoctoral Fellow – Solid Tumor Microenvironment Research (H. Lee Moffitt Cancer Center & Research Institute)

Postdoctoral Position – Prostate Cancer (University of Washington)

Head – Single Cell Research (Sloan Kettering Institute)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.